PureTech Health (NASDAQ:PRTC) Stock Price Up 1.2%

PureTech Health plc (NASDAQ:PRTCGet Rating)’s stock price rose 1.2% on Friday . The company traded as high as $30.80 and last traded at $29.39. Approximately 203 shares were traded during mid-day trading, a decline of 85% from the average daily volume of 1,333 shares. The stock had previously closed at $29.05.

Wall Street Analysts Forecast Growth

PRTC has been the topic of a number of research analyst reports. Piper Sandler boosted their price target on shares of PureTech Health from $37.00 to $44.00 and gave the stock an “overweight” rating in a report on Thursday, August 25th. SVB Leerink cut their price target on shares of PureTech Health from $70.00 to $66.00 and set an “outperform” rating on the stock in a report on Wednesday, June 15th.

PureTech Health Trading Down 2.7 %

The company has a current ratio of 2.54, a quick ratio of 2.22 and a debt-to-equity ratio of 0.02. The company’s fifty day simple moving average is $27.36 and its 200 day simple moving average is $25.08.

Institutional Investors Weigh In On PureTech Health

A hedge fund recently raised its stake in PureTech Health stock. AWM Investment Company Inc. raised its holdings in shares of PureTech Health plc (NASDAQ:PRTCGet Rating) by 2,100.0% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 660,000 shares of the company’s stock after purchasing an additional 630,000 shares during the quarter. AWM Investment Company Inc. owned approximately 2.32% of PureTech Health worth $2,513,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 2.32% of the company’s stock.

About PureTech Health

(Get Rating)

PureTech Health plc, a clinical-stage biotherapeutics company, discovers, develops, and commercializes medicines for inflammatory, fibrotic and immunological, intractable cancers, lymphatic and gastrointestinal, neurological and neuropsychological, and other diseases in the United States. The company offers KarXT targeting muscarinic acetylcholine receptors to treat schizophrenia and psychosis in Alzheimer's disease; a regenerative biology platform for androgenetic alopecia, epithelial ageing, and other medical conditions; an immunomodulation platform to treat chronic and acute inflammatory disorders; oral therapies based on defined consortia of bacteria is isolated from the human microbiome; and therapies to treat cognitive dysfunction associated with depression, multiple sclerosis, post COVID and ICU, and cancer related conditions.

Featured Articles

Receive News & Ratings for PureTech Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PureTech Health and related companies with MarketBeat.com's FREE daily email newsletter.